Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice

Manuscript Number: 

14-2421R2

Author(s): 
Soumee Bhattacharya, Alfred Maelicke, Dirk Montag

Disclosures

Soumee Bhattacharya

  • Nothing to Disclose

Alfred Maelicke

  • Equity:
    Founder, CEO and minority shareholder of Galantos Pharma GmbH
    Patents/Royalties
    EU patent: WO 2009/127218 A1: Derivatives of Galantamines as Pro-Drugs for the Treatment of Human Brain Diseases

Dirk Montag

  • Nothing to Disclose